PSMA Academy VL

PSMA PET Before and After PSMA Radioligand Therapy (Mismatch Example Liver Mets) PSMA PET for Response Monitoring - Bernd Krause & Oliver Sartor

Details
In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Oliver Sartor and Bernd Krause discuss PSMA-PET/CT before and after PSMA radioligand therapy with mismatch example for liver metastases. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Prof. Dr. med. Bernd J. Krause, Nuclear Medicine Physic...

Pitfalls and Controversial Cases with PSMA PET CT - Stefano Fanti, Christopher Sweeney, & Neal Shore

Details
In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Stefano Fanti, Christopher Sweeney, and Neal Shore discuss a controversial topic on what to do when you have bone findings at PSMA PET with no CT counterpart. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Stefano Fanti, MD, Professor, Dep...

PSMA PET for Primary Staging (high risk localized, N1, M1) - Thomas Hope, Bertrand Tombal, Nicola Fossati, and Robert Reiter

Details
In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Thomas Hope, Nicola Fossati, Robert Reiter, and Bertrand Tombal discuss a series of five cases focusing on how PSMA-PET impacts the management of prostate cancer patients. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Thomas Hope, MD, Ass...

Reading and Reporting a PSMA PET Scan for Staging Prostate Cancer - Andrea Farolfi

Details
In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Andrea Farolfi presents the clinician's view on reading and reporting a PSMA PET scan. He highlights the PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE) as well as PSMA PET progression criteria (PPP) to define prostate cancer progression by PSMA PET and what is important in a PS...

Understanding Physiological PSMA Biodistribution - Jeremie Calais

Details
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Jeremie Calais, MD, MSc, Director, Clinical Research Pro...

The Dark Side of PSMA: Pitfalls, Limits, and ADT - Matthias Eiber

Details
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Drs Matthias Eiber and Thomas Langbein jointly prepared and Dr Eiber presents on the Dark Side of PSMA: Pitfalls, Limits, and ADT for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Matthias Eiber, MD, PhD, Department of Nuclear Medici...

PSMA PET in the Metastatic Castration-Resistant Prostate Cancer Setting - Oliver Sartor

Details
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA treatment, Oliver Sartor presents PSMA PET in the metastatic castration-resistant prostate cancer setting with the goal of treatment and an outlook on PSMA therapy. He focuses on this in the context of The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. Independent Medical Educat...

How to Perform a PSMA PET Scan - Wolfgang Fendler and Stephan Himmen

Details
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Drs Wolfgang Fendler and Stephan Himman jointly present "How to Perform a PSMA PET Scan". Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Wolfgang Fendler, MD, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (D...

The Mechanism of PSMA PET for Prostate Cancer - Stefano Fanti and Ken Herrmann

Details
In this educational initiative, Stefano Fanti and Ken Herrmann join together to share their knowledge of PSMA PET and PSMA theranostics focusing on the mechanism of PSMA PET imaging, different PET tracers, differences between FDG-PET and PSMA-PET, as well as the concept of PSMA and theranostics. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies:...
email news signup